TWA
SIOX

TCI Wealth Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

TCI Wealth Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-400
Closed – – 2699
2022
Q3 		$0 Sell
400
-300
-43% -$103 ﹤0.01% 2698
2022
Q2 		$0 Hold
700
– – ﹤0.01% 2607
2022
Q1 		$0 Buy
+700
New +$594 ﹤0.01% 2553
2021
Q4 		– Sell
-1,400
Closed -$3K – 2598
2021
Q3 		$3K Buy
+1,400
New +$3.04K ﹤0.01% 2069
2021
Q2 		– Sell
-2,500
Closed -$7K – 2516
2021
Q1 		$7K Sell
2,500
-100
-4% -$283 ﹤0.01% 1101
2020
Q4 		$7K Buy
2,600
+2,500
+2,500% +$7.28K ﹤0.01% 783
2020
Q3 		$0 Buy
+100
New +$330 ﹤0.01% 1702
2020
Q2 		– Sell
-4,000
Closed -$10K – 1721
2020
Q1 		$10K Buy
+4,000
New +$14.4K ﹤0.01% 578

Other funds holding SIOX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCI Wealth Advisors's SIOX Position: Q4 2022 in Review

TCI Wealth Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2022, closing a stake of 400 shares.

TCI Wealth Advisors first reported a position in SIOX in Q1 2020 and held it in 8 quarters. The position peaked at $10K in Q1 2020. 37 funds tracked by Wall St. Rank hold SIOX as of Q4 2022.

  • TCI Wealth Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 400 Sio Gene Therapies Inc. Common Stock shares in Q4 2022.
  • TCI Wealth Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2020 and held it in 8 quarters.
  • TCI Wealth Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $10K in Q1 2020.
  • 37 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2022.

Based on TCI Wealth Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.